Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus FLUTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus FLUTEX.
ALA-CORT vs FLUTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Flutamide is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone (DHT) to androgen receptors in target tissues, thereby blocking the androgenic effects.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
50 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life: 24–36 hours, permitting once-daily dosing in chronic therapy
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Renal: ~70% (50% unchanged, 20% as metabolites); Biliary/fecal: ~30%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid